Schering Peginterferon European Indication Restricted To Rebetron Failures
Schering-Plough's peginterferon alfa-2b should be used as monotherapy in hepatitis C patients who have failed or are intolerant to ribavirin in interferon-alfa/ribavirin combination therapy (Rebetron), the European Committee for Proprietary Medicinal Products recommends.
You may also be interested in...
Janssen and Alkermes are collaborating to develop a depot formulation of the antipsychotic Risperdal that would be delivered via injection once every two weeks. Risperdal is currently available in daily tablet or oral solution formulations.
Roche expects to file a BLA for its pegylated interferon alpha product Pegasys for hepatitis C in 2000, Roche Clinical Science-Virology Director Joseph Hoffman, MD, reported at a Roche R&D meeting in Basel June 14-15.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011